PD
CTKB icon

Point72 (DIFC)’s Cytek Biosciences CTKB Stock Holding History

Point72 (DIFC)’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$71.1K Buy
20,489
+12,308
+150% +$46.2K ﹤0.01% 659
2025
Q2 		$27.8K Buy
8,181
+1,611
+25% +$5.37K ﹤0.01% 1180
2025
Q1 		$26.3K Buy
+6,570
New +$34K ﹤0.01% 1311

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 (DIFC)'s CTKB Position: Q3 2025 in Review

Point72 (DIFC) increased its Cytek Biosciences (CTKB) stake by 150% in Q3 2025, buying an estimated $46.2K and bringing the position to 20,489 shares worth $71.1K. The position accounts for ﹤0.01% of the portfolio, ranked #659.

Point72 (DIFC) first reported a position in CTKB in Q1 2025 and has held it in 3 quarters since. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • Point72 (DIFC) held 20,489 shares of Cytek Biosciences worth $71.1K as of Q3 2025.
  • Point72 (DIFC) bought 12,308 Cytek Biosciences shares in Q3 2025, an estimated $46.2K.
  • Cytek Biosciences made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #659 holding.
  • Point72 (DIFC) first reported a position in Cytek Biosciences in Q1 2025 and has held it in 3 quarters since.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.